NCT07570940
A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery
At risk: Primary completion moved at least 2 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 23 words
- Start date changed from estimate of Sep 14, 2026 to Sep 29, 2026
- Secondary endpoints: details revised at 1 of 2 entries
- Site details revised
- Notable Start date: Jun 2026 to Sep 14, 2026
- Primary and study completion pushed from Jun 2030 to Sep 2030
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of new-onset postoperative atrial fibrillation (POAF) within one week of isolated coronary artery bypass grafting (CABG) surgery
Timeframe: 1 week
Secondary (2)
Total duration of postoperative atrial fibrillation (POAF) episodes within the first postoperative week
Number of patients with successful stellate ganglion blockade
Arms and interventions
Stellate ganglion block using liposomal bupivacaineExperimental
10 mL of liposomal bupivacaine 133 mg (133 mg/10 ml or 1.33%)
Sham block using saline placeboPlacebo comparator
10 mL of saline placebo injected in the plane of the right stellate ganglion
Drugs: Liposomal bupivacaine, Placebo
Sites
1 site in 1 country
- Mayo Clinic in RochesterRochester, Minnesota, United States